New drug improves progression-free survival, shrinks tumors in rare cancer for first time

(Memorial Sloan-Kettering Cancer Center) The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news